Spectral AI Investor Presentation
Spectral AI filed a formal investor presentation deck detailing its commercialization strategy for the DeepView System following its May 2026 FDA De Novo classification. The presentation highlights the company's $250 million in non-dilutive government funding and its $150 million contracted revenue base with BARDA for burn and trauma center deployments. The company is transitioning from clinical validation to commercial launch in the US, UK, and Australia.